{
"@context": "/terms/",
"@id": "/construct-library-sets/IGVFDS6128KVUP/",
"@type": [
"ConstructLibrarySet",
"FileSet",
"Item"
],
"accession": "IGVFDS6128KVUP",
"aliases": [
"jesse-engreitz:IL2RAtiling-pegRNALibrarySequencing"
],
"applied_to_samples": [
{
"@id": "/in-vitro-systems/IGVFSM1981RVAJ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1981RVAJ",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep1"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9146UAUA/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9146UAUA",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep1-BinB"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM1409FVBR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1409FVBR",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep3-BinC"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8167KBIF/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8167KBIF",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM5247TRTU/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM5247TRTU",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep3"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9871LEEE/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9871LEEE",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM0936EYTX/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM0936EYTX",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep2"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM6795SCHR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM6795SCHR",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep2-BinA"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7352WPEI/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7352WPEI",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep2-BinB"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM5709XAIS/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM5709XAIS",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep3-BinD"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9101ODMK/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9101ODMK",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep1"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7154EMJR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7154EMJR",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep3"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9297KXBW/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9297KXBW",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep1-BinA"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8750WCGQ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8750WCGQ",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep3-BinA"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4883HGPU/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4883HGPU",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep3-BinB"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4954YHLR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4954YHLR",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep1-BinC"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9103RFFD/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9103RFFD",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep1-BinD"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8079DJVX/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8079DJVX",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep2-BinC"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9448WLVQ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9448WLVQ",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep1-FFRep2-BinD"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4933EQTP/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4933EQTP",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep2"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM1871BLFB/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1871BLFB",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep3-BinD"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7312DZBH/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7312DZBH",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep1-BinA"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM1469NQHM/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1469NQHM",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep1-BinB"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4784GKZI/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4784GKZI",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep1-BinC"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM3690RUXJ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM3690RUXJ",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep2-BinB"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM2690PEZO/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM2690PEZO",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep1-BinD"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM2330LAXQ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM2330LAXQ",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep2-BinA"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9894RFCK/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9894RFCK",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep2-BinC"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4553KVCE/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4553KVCE",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep2-BinD"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM5388SXBN/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM5388SXBN",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep3-BinA"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8345LMXC/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8345LMXC",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep3-BinB"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7206IJBO/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7206IJBO",
"aliases": [
"jesse-engreitz:Jurkat_Stim-IL2RA_prom-BioRep2-FFRep3-BinC"
],
"classifications": [
"cell line"
],
"donors": [
{
"@id": "/human-donors/IGVFDO1080XFGV/",
"status": "released",
"taxa": "Homo sapiens"
}
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Jurkat cell line, male, Homo sapiens (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transfected with a guide library",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
}
],
"audit": {
"INTERNAL_ACTION": [
{
"category": "missing sequencing kit",
"detail": "Construct library set [IGVFDS6128KVUP](/construct-library-sets/IGVFDS6128KVUP/) has sequence file(s) [IGVFFI3027JYLB](/sequence-files/IGVFFI3027JYLB/), [IGVFFI3514ALUV](/sequence-files/IGVFFI3514ALUV/), [IGVFFI2649OSZF](/sequence-files/IGVFFI2649OSZF/) which lack specification of a `sequencing_kit`. Sequence files should specify a sequencing kit.",
"level": 30,
"level_name": "INTERNAL_ACTION",
"name": "audit_inconsistent_sequencing_kit",
"path": "/construct-library-sets/IGVFDS6128KVUP/"
},
{
"category": "missing sequence specification",
"detail": "Construct library set [IGVFDS6128KVUP](/construct-library-sets/IGVFDS6128KVUP/) has sequence file(s): [IGVFFI3027JYLB](/sequence-files/IGVFFI3027JYLB/), [IGVFFI3514ALUV](/sequence-files/IGVFFI3514ALUV/), [IGVFFI2649OSZF](/sequence-files/IGVFFI2649OSZF/) which do not have any `seqspecs`. Sequence files in a file set are expected to link to a sequence specification file.",
"level": 30,
"level_name": "INTERNAL_ACTION",
"name": "audit_missing_seqspec",
"path": "/construct-library-sets/IGVFDS6128KVUP/"
}
],
"NOT_COMPLIANT": [
{
"category": "missing plasmid map",
"detail": "Construct library set [IGVFDS6128KVUP](/construct-library-sets/IGVFDS6128KVUP/) does not have a plasmid map attached in `documents`. Construct library sets are expected to be associated with a plasmid map document.",
"level": 50,
"level_name": "NOT_COMPLIANT",
"name": "audit_construct_library_set_plasmid_map",
"path": "/construct-library-sets/IGVFDS6128KVUP/"
},
{
"category": "missing guide RNA sequences",
"detail": "Construct library set [IGVFDS6128KVUP](/construct-library-sets/IGVFDS6128KVUP/) has no `integrated_content_files`. Guide libraries are expected to link to an integrated content file of guide RNA sequences.",
"level": 50,
"level_name": "NOT_COMPLIANT",
"name": "audit_integrated_content_files",
"path": "/construct-library-sets/IGVFDS6128KVUP/"
},
{
"category": "missing analysis",
"detail": "Construct library set [IGVFDS6128KVUP](/construct-library-sets/IGVFDS6128KVUP/) is a raw data set with files, but is not listed in any `input_file_sets` for any analysis sets. Raw data sets with files are expected to be associated with at least one analysis set.",
"level": 50,
"level_name": "NOT_COMPLIANT",
"name": "audit_input_for",
"path": "/construct-library-sets/IGVFDS6128KVUP/"
}
]
},
"average_guide_coverage": 111,
"award": {
"@id": "/awards/HG011972/",
"component": "functional characterization"
},
"control_for": [],
"creation_timestamp": "2024-11-21T21:02:35.104502+00:00",
"file_set_type": "guide library",
"files": [
{
"@id": "/sequence-files/IGVFFI3027JYLB/",
"accession": "IGVFFI3027JYLB",
"aliases": [
"jesse-engreitz:IL2RA_Promoter_Tiling-pegRNALibrarySequencing_R1"
],
"content_type": "reads",
"file_format": "fastq",
"status": "preview",
"upload_status": "validated"
},
{
"@id": "/sequence-files/IGVFFI3514ALUV/",
"accession": "IGVFFI3514ALUV",
"aliases": [
"jesse-engreitz:IL2RA_Promoter_Tiling-pegRNALibrarySequencing_I1"
],
"content_type": "reads",
"file_format": "fastq",
"status": "preview",
"upload_status": "validated"
},
{
"@id": "/sequence-files/IGVFFI2649OSZF/",
"accession": "IGVFFI2649OSZF",
"aliases": [
"jesse-engreitz:IL2RA_Promoter_Tiling-pegRNALibrarySequencing_R2"
],
"content_type": "reads",
"file_format": "fastq",
"status": "preview",
"upload_status": "validated"
}
],
"guide_type": "sgRNA",
"input_for": [],
"lab": {
"@id": "/labs/jesse-engreitz/",
"title": "Jesse Engreitz, Stanford"
},
"schema_version": "10",
"scope": "loci",
"selection_criteria": [
"sequence variants"
],
"small_scale_loci_list": [
{
"assembly": "GRCh38",
"chromosome": "chr10",
"end": 6062689,
"start": 6062505
}
],
"sources": [
"/sources/agilent/"
],
"status": "preview",
"submitted_by": {
"@id": "/users/f9e7cd82-a407-4a20-89ee-f4dc668b0cbe/",
"title": "Michael Montgomery"
},
"submitted_files_timestamp": "2024-11-21T21:40:10.269663+00:00",
"submitter_comment": "sequencing of plasmid library containing pegRNAs for tiling mutagenesis ofIL2RA promoter. Tiling region was split into 5-bp increments and pegRNAs were designed to introduce 3 5-bp mutagenesis substitutions at each tile",
"summary": "guide (sgRNA) library targeting sequence variants in a genomic locus",
"uuid": "26449462-b132-470b-aaf6-8d17725819fe"
}